Comprehensive Review on Pathogenesis and Management in Sickle Cell Anemia

Sanskruti S. Maske[1], Vidyanand N. Khairnar[2], Prof. Neha L. Zod[3], Prof. Nikita V. Mahalle[4], Dr. Harigopal S. Sawarkar[5]

[1]Student,[2]Student,[3]Associate Professor, [4]Associate Professor, [5]Principal

[1,2]B. Pharm Final Year Student, Dr. Rajendra Gode College of Pharmacy, Amravati-444602, Maharashtra (India)

[3]Department of Pharmacology, Dr. Rajendra Gode College of Pharmacy, Amravati-444602, Maharashtra (India)

[4]Department of Pharmacology, Dr. Rajendra Gode College of Pharmacy, Amravati-444602, Maharashtra (India)

[5]Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Amravati-444602, Maharashtra (India)

Abstract

Sickle cell disease (SCD) represents a severe medical condition with potentially fatal outcomes. Considering the disorder's characteristics and its related complications that result in elevated death and illness rates, early identification during infancy is essential, along with immediate connection to both specialized and general paediatric medical services, ensuring uninterrupted healthcare delivery. A portion of individuals with SCD belong to disadvantaged, high-risk groups. These groups often encounter significant social obstacles leading to delayed or absent diagnosis, consequently postponing treatment and substantially elevating the likelihood of illness and death. Detection methods like state wide infant screening programs facilitate early identification. Nevertheless, individuals from disadvantaged, high-risk populations who lack integration into the healthcare framework may miss crucial communication regarding their condition and required subsequent care measures. We describe a case involving a one-year-old girl who exemplifies numerous individuals who, despite undergoing infant screening, were overlooked because of social challenges including residential instability, inadequate food access, and insufficient transportation options. This article highlights the necessity for and demonstrates an actual illustration of how access to ongoing primary healthcare benefits disadvantaged individuals. We further illustrate primary care's function in bridging healthcare disparities and rapidly organizing services to ultimately avert life-threatening complications, particularly for children with previously unidentified chronic conditions.

Keywords: Haemoglobin disorder, healthcare accessibility, paediatric medicine, prophylaxis, first-line healthcare, vulnerable populations, chronic medical condition.

Introduction

Sickle cell disease (SCD) encompasses a collection of blood disorders involving genetic alterations in the beta-globin chain of haemoglobin. The initial documentation of an SCA-resembling condition was presented by dr. Africanus Horton in his publication. Diseases Found in Tropical Regions and Their Management (1872). Nevertheless, recognition did not occur until 1910 when dr.James B Herrick and dr. Ernest Irons documented observing crescent-shaped red blood cells in a dental student (Walter Clement Noel from Grenada). In 1949, separate publications from dr.James V Neel and Col. E. A. Beet outlined the hereditary patterns in individuals with SCD. During the same year, dr. Linus Pauling characterized the molecular structure of sickle haemoglobin (HbS) in his research paper titled 'Sickle Cell Anaemia Haemoglobin.' Ingram Vernon, in 1956, employed a fingerprinting methodology to identify the substitution of negatively charged glutamine with neutral valine, confirming Linus Pauling's discoveries. [1]

Under the classification of SCD, numerous subcategories are present, specifically sickle cell anaemia (SCA), haemoglobin SC disease (HbSC), and haemoglobin sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Multiple additional minor variants within the SCD category also exist, though less prevalent than the previously mentioned types. Finally, noteworthy is the sickle cell trait (HbAS), which possesses a heterozygous genetic alteration and rarely exhibits clinical manifestations or symptoms. Sickle cell anaemia represents the most prevalent variant of SCD,

characterized by chronic haemolytic anaemia necessitating blood transfusions, painful episodes, and organ deterioration. [2]

Following the initial observation of the abnormal crescent-shaped red blood cells (RBC) over a century ago, our comprehension of this condition has progressed remarkably. Contemporary developments in this area, particularly during the past three decades, have improved symptoms for numerous individuals, especially in wealthy nations. In 1984, Platt et al. Initially documented the utilization of hydroxyurea in elevating HbF concentrations. Subsequently, sickle cell treatment has advanced significantly through the introduction of multiple novel medications (voxelotor, crizanlizumab, L-glutamine) and, most recently, genetic therapy. [3]



Fig: Normal red blood cells vs Sickle cell red blood cells [4]



Fig: Inheritance of sickle cell anemia [5]

Fig: Yellow eyes in sickle cell patient [6]

Fig: Leg ulcer in patient with sickle cell disease [7]

Etiology

Haemoglobin (Hb) represents a crucial protein contained within red blood cells (RBC). It consists of four globin molecules, two originating from alpha-globin (genetic location on chromosome 16) and two from beta-globin (genetic location on chromosome 11). Numerous variations of Hb exist. The most prevalent types identified in adults without blood disorders are presented here: HbA1- consists of two alpha-globin molecules and two beta-globin molecules (a2b2) – This comprises 95% of adult haemoglobin. [8]

HbA2- consists of two alpha-globin molecules and two delta-globin molecules (a2d2) – This comprises less than 4% of adult haemoglobin. [9]

HbF- consists of two alpha-globin molecules and two gamma-globin molecules (a2g2) – This Hb is more abundant in fetal circulation (attributable to the elevated oxygen attachment capacity that facilitates oxygen extraction from maternal bloodstream). [10] The sickle cell genetic alteration develops when negatively charged glutamate is substituted by a neutral valine at position six of the beta-globin molecule. The genetic alteration is passed through Mendelian inheritance patterns and is transmitted in an autosomal codominant manner. [11] A homozygous genetic alteration results in the most severe variant of SCD, specifically SCA- also termed HBSS condition. The simultaneous inheritance of beta-zero thalassemia and sickle cell genetic alteration produces HBS-Beta-0 condition, which clinically resembles HBSS condition. [12] A heterozygous inheritance produces HbAS. Individuals with HbAS are not classified within the range of SCD since the majority never exhibit characteristic manifestations of SCA. They might only be identified during pregnancy, blood contribution, or examination protocols. [13] Multiple additional compound heterozygous combinations exist where a single

variant of the altered beta-globin sequence is simultaneously inherited with a single variant of another altered sequence. [14] The second most prevalent variation of SCD is HbSC condition, where the sickle cell sequence is simultaneously inherited with a single variant of the altered haemoglobin C sequence. HbC develops when lysine substitutes glutamine at position six on the beta-globin molecule. HbSC condition represents 30% of individuals in the United States. [15]

Epidemiology

The demographic information regarding SCD is limited. It is widely recognized that SCD and HbAS are more widespread in sub-Saharan Africa, where carriers of HbAS receive inherent defences against serious Plasmodium falciparum malaria infection. It is calculated that approximately 230,000 infants were delivered with SCA, and over 3.5 million new-borns were delivered with HbAS in sub-Saharan Africa in 2010. [16] An estimated 75% of SCD-associated deliveries occur in sub-Saharan Africa. West Africa houses the largest concentration of individuals with HbSC condition. [17] The United States (US) Centre for Disease Control (CDC) approximates that roughly 100,000 Americans possess SCD. The CDC also approximates that 1 in 13 infants delivered to African-American parents possess sickle cell trait, and 1 in 365 African-Americans possess SCD. [18] The calculated proportion of Hispanic Americans with SCD is 1 in 16,300. Children and young adults constitute up to 40% of all SCD individuals in the US. The occurrence fluctuates by region and geographic distribution of ethnic groups. Furthermore, relocation within the nation and immigration from international locations modify the frequency of SCD and HbAS. This holds true for multiple nations where individuals with SCD and SCA reside. [19] Hereditary research in Brazil has also connected the ancestry of such individuals to the slave trade originating from West Africa (Mina Coast and Angola). With the advancement in medical technology and facilitation of global movement, the occurrence of SCA is anticipated to increase. It is calculated that the yearly number of new born with SCA will surpass 400,000 by 2050.There exists a significant disparity in death rates and illness rates in wealthy and developing nations. [20] Implementation of immunization protocols for children with SCD and comprehensive examination procedures has dramatically decreased the mortality of youngsters with SCD between 0 to 4 years (68% reduction observed from 1999 to 2002 compared to 1983 to 1986). Conversely, in sub-Saharan Africa, 50 to 90% of children delivered with SCD will perish before reaching their fifth year. Enhancing the medical attention provided in wealthy nations and focused education of medical professionals have extended life expectancy. Nevertheless, it remains decades behind compared to equivalent non-SCD populations (54 versus 76 years – anticipated life expectancy, and 33 years versus 67 years- quality-adjusted life expectancy).HbSC condition represents 30% of all individuals with SCD in the US. Similar to HbAS, individuals with the Hb C trait (heterozygous genetic alteration) also remain without symptoms for the majority of their existence. Although regarded as a less severe variation of SCD, HbSC condition may exhibit serious health complications. [21]



Fig: Number of people living with sickle cell disease [22]

Pathophysiology

Sickle cell anaemia is defined by two principal elements: Haemolysis and vascular obstruction episodes (VOC). The abnormality in the beta-globin sequence renders the sickle haemoglobin (HbS) molecule vulnerable to transformation into rigid, extended polymeric structures in an oxygen-depleted condition. [23] The sickling mechanism is initially cyclical,

where sickle erythrocytes alternate between the standard biconcave configuration and the irregular crescent configuration (obtained under reduced oxygen tension). Nevertheless, eventually the transformation becomes permanent, and the sickle erythrocytes acquire a lasting sickle configuration, elevating the likelihood for haemolysis and VOC. [24] All variations of SCD possess identical pathophysiological mechanisms resulting in polymerization of the HbS element. Several characteristics intrinsic to sickle erythrocytes, including the reduced attraction of HbS for oxygen, physiologically elevated 2,3-diphosphoglycerate, and enhanced sphingokinase-1 function, result in deoxygenation, which facilitates the polymerization of HbS. Beyond this, an elevated level of HbS, irregular function of the Gados channel resulting in dehydration, and continuous injury to the red blood cell (RBC) surface also elevate the likelihood of polymerization of HbS. Oxidative damage contributes to haemolysis through auto-oxidation of HbS, resulting in erythrocyte cellular surface injury. [25] The elevated presence of xanthine dehydrogenase, xanthine oxidase, and reduced presence of NADPH oxidase enhance the oxidative damage within sickle RBC. [26] A haemolyzed cellular unit releases unbound haemoglobin (captures nitrous oxide) and arginase 1 (competes for L-arginine) that inhibit the function and generation of nitrous oxide and contribute to oxidative damage and vascular restructuring (arginase-1 transforms arginine to ornithine). Apart from the polymerization of the HbS and intravascular haemolysis, multiple additional elements also contribute to vascular obstruction. For instance, the sickle RBC (displays multiple attachment molecules on the exterior), unbound haem and Hb, reactive oxygen compounds, and endothelium interact with one another and with neutrophils and platelets to facilitate vascular obstruction and blood clot formation. [27]

Histopathology

In individuals with SCA, peripheral blood examination reveals elongated RBC with narrowing extremities that resemble a sickle (also termed drepanocytes). Supplementary observations are present in certain individuals. Howell-Jolly bodies- Fragments of DNA are visible in the RBC and frequently observed in individuals in whom the spleen has been extracted. Consequently, individuals with SCA experience auto-splenectomy. [28] Target cells (Leptocytes). Most frequently observed in individuals with Thalassemia. They are observed regularly in sickle-thalassemia conditions and are occasionally noted in individuals with SCA.Nucleated red blood cells can occasionally be visible on the peripheral examination. None of these observations are conclusive. Verification is acquired only through haemoglobin electrophoresis, high-performance liquid chromatography, or isoelectric focusing. [29] DNA-based methodologies are not utilized routinely. Rather, they are utilized in individuals with ambiguous diagnoses. Prenatal fetal examination involves utilizing fetal DNA acquired through amniocentesis. Methodologies to capture the fetal DNA in maternal bloodstream remain under investigation. [30]

History and Physical

The majority of individuals with HbSS phenotype do not exhibit characteristic ‘sickle cell crises’ immediately following delivery. HbF remains present in the circulation, facilitating maintenance of sufficient tissue oxygenation, and requires approximately 6-9 months to completely diminish. Not all SCAs possess identical phenotypes, and multiple phenotypic variations exist that can either coexist or manifest as a continuum of the condition. Vaso-occlusive sub phenotype – Characterized by elevated haematocrit (Hct) relative to other SCA. An elevated Hct results in increased viscosity that facilitates frequent vascular obstruction episodes and acute chest syndrome. [31]

Pain-sensitive sub phenotype- Modified neurophysiology among different individuals renders them vulnerable to pain. Certain individuals are more vulnerable to pain relative to others with SCA. The individuals with SCA manifest with acute or chronic complications related to the condition. The most frequent acute complication of SCA is vascular obstruction episode (VOC). The treatment section below addresses the management of acute and chronic problems. Significant aspects to be documented in the clinical history of individuals with SCA all individuals with SCA will encounter VOC during their existence. The earliest manifestation is dactyllitis in youngsters as early as six months of age. [32]

History of obtaining blood transfusions and exchange transfusions- facilitates assessment of the likelihood of iron accumulation, existence of alloantibodies (numerous transfusions in the past can result in the formation of alloantibodies, which will facilitate assessment of the likelihood of transfusion reactions), and prior transfusion reactions. [33]

History of life-threatening episodes in the past- if present, should alert the physician to verify that a comparable occurrence is not happening again. For instance, fat embolism may develop more regularly in individuals with SCA. The physical examination should concentrate on the general system assessment to establish the requirement for oxygen supplementation, pain management, and blood/exchange transfusion. Nevertheless, a targeted examination is essential to exclude any organ-specific issue. For instance, a quickly enlarging liver or spleen should notify the physician about sequestration episodes. [34]

Evaluation

Individuals with SCA are typically identified during childhood. Comprehensive newborn examination programs in developed nations can recognize individuals in the neonatal phase. In the US, universal examination for SCA was established in all regions by 2007. High-performance liquid chromatography and isoelectric focusing are the methodologies utilized in the US. In Europe, the majority of nations implement focused examination in high-risk locations (where SCA is more prevalent) and not a universal examination. [35] In sub-Saharan Africa, no nation has implemented an examination program. In India, the solubility test is utilized as the initial step- if positive, then high-performance liquid chromatography is utilized to verify at the reference facilitate acute Complications in Individuals with SCA. [36]

Acute Chest Syndrome (ACS): ACS is the most frequent complication of SCA. It is also the most frequent cause of mortality and the second most frequent cause of hospital admission. An individual can either manifest with ACS or may develop it during hospitalization for any other reason. Therefore, it is advisable to observe all individuals with SCA admitted to the hospital for ACS. It is crucial to identify ACS early and address it to prevent respiratory failure. The risk elements for ACS include a prior history of ACS, asthma, or recent occurrences like recent surgical interventions, pulmonary embolism, fluid accumulation, infection, etc. [37]

The clinical characteristics include sudden onset of cough and respiratory difficulty. Fever may or may not be a component of the spectrum of manifestation. If present, then it typically indicates infection. [38]

Laboratory assessment includes a complete blood count with differential chemistries, including liver and kidney assessment, blood cultures, and sputum cultures.

Chest X-ray reveals a new pulmonary infiltrate- this is an essential characteristic of defining ACS. CT and perfusion mismatch scans are only utilized if there is a strong clinical suspicion of pulmonary or fat embolism. Consequently, they are not typically beneficial in acute settings. Sequestration Crises: This can either be hepatic or splenic sequestration. Splenic sequestration is a major cause of acute anaemia.

Individuals experience rapid spleen enlargement related to pain in the left upper quadrant. In children with SCA, it is frequent in children between 1 to 4 years of age, as the spleen remains intact. [39]

Acute Stroke: Cerebrovascular accident is the most devastating complication of SCA. Since the introduction of transcranial Doppler (TCD) and the establishment of primary prevention programs, the occurrence of cerebrovascular accident has decreased in individuals with SCA. In the absence of primary prevention, approximately 10% of children suffer from overt cerebrovascular accident, and roughly 20 to 35% have silent cerebral infarcts. TCD is not beneficial for adults. Severe headache, altered mental status, slurred speech, seizures, and paralysis are indications of cerebrovascular accident.

Urgent neurological consultation and CT scan followed by MRI/MRA must be performed. [40]

Treatment / Management

Individuals with SCA manifest with acute and chronic complications. Management of Acute Complications Pain Management: Pain control represents a crucial element of SCA management. It poses challenges for physicians to precisely evaluate individuals' requirements, particularly during initial encounters. Individuals with SCA frequently experience stigmatization due to requiring elevated doses of opioids for pain relief, which results in them being characterized as opioid misusers, manipulators, or medication seekers. Analgesic delivery commences concurrently with identifying the cause, optimally within 30 minutes of triage and 60 minutes of registration. [41]

Formulate individualized pain control strategies – these should be accessible to emergency facilities and should be executed whenever the individual manifests with VOC and pain. NSAIDs are utilized in individuals with mild to moderate pain who document previous instances of relief with NSAIDs. [42]

Opioids: Any individual manifesting with serious pain- preferably utilize parenteral opioids. An intravenous pathway is preferred; nevertheless, if access proves challenging, utilize the subcutaneous pathway. The dosage of parenteral opioids is determined based on the total dosage of short-actuing oral opioids consumed at home. Pain should be re-evaluated every 15 to 30 minutes, and re-administer opioids if necessary. The escalation of opioids occurs in 25 percent increments. Patient-controlled analgesia (PCA) is preferred. If an on-demand configuration is utilized in PCA, then continue long-acting analgesia. When pain control is accomplished, taper parenteral opioids before transitioning to oral medications. Calculate the inpatient analgesic requirement at discharge and modify home dosages of short and long-acting opioids accordingly. Meperidine is not utilized in managing VOC-related pain unless this is the sole medication that controls the pain. [43]

Encourage individuals to explore alternative methods of controlling pain, including direct massage, self-hypnosis, and music therapy. Acute Chest Syndrome (ACS): It represents an emergency regardless of the sickle cell disease phenotype. It can result in respiratory failure and mortality if not managed as an emergency. All individuals must be hospitalized. [44]

ACS is a strong indicator for initiating disease-modifying therapy including hydroxyurea, or starting the individual on a chronic blood transfusion program. Sequestration Crises Intravenous fluids for hydration, pain control, and simple or exchange blood transfusion are central to managing sequestration crises.

For children with a temperature equal to or greater than 101.3°F (38.5°C), deliver parenteral antibiotics with coverage against Streptococcus pneumoniae and gram-negative enteric organisms. [45]

Differential Diagnosis

Generally, globin sequence alterations affecting haemoglobin are widespread and impact 7 percent of the global population. More than 1000 variations of haemoglobin are present. Nevertheless, only a limited number of variations are clinically meaningful. Frequent Variants of SCA or HbSS Condition Haemoglobin S-beta-0 thalassemia – Clinically demonstrates identical behaviour to HbSS condition

Haemoglobin SC – a less severe variant of SCD – can exhibit a phenotypic manifestation of sickle cell anaemia.

Haemoglobin S-beta+ thalassemia – a less severe variant of SCD Multiple additional haemoglobin variants are present that can resemble SCA if they are transmitted along with HbS. Haemoglobin Jamaica-Plain – beta-68 [E12] Leu to Phe

Haemoglobin Quebec- Chori – beta-87 [F3] Thr to Ile

Haemoglobin D-Punjab – beta-globin, codon 121, glutamine to glutamic acid

Haemoglobin O-Arab

Haemoglobin E Additional conditions that can manifest with haemolysis, where SCA can be excluded with clinical history, physical examination, haemoglobin electrophoresis, and analysis of the peripheral blood film Antibody-mediated autoimmune haemolytic anaemia – both warm and cold antibodies. [46]

Other blood disorders- alpha or beta-thalassemia

Paroxysmal nocturnal haemoglobinuria

RBC-membrane abnormalities including hereditary spherocytosis and hereditary elliptcytosis

Enzyme abnormalities including pyruvate kinase deficiency and glucose-6-phosphate deficiency

Medication-induced haemolysis

Transfusion-associated haemolysis including acute or delayed haemolytic reaction

Micro angiopathic haemolytic anaemia including atypical or typical haemolytic uremic syndrome and thrombotic thrombocytopenic purpura

Infectious aetiologies including malaria, babesiosis, Rickettsia, Clostridia, and Bartonella Vasculitis-associated haemolysis. [47]

Medical Oncology

The objective of disease-modifying therapy in sickle cell anaemia is to diminish the frequency of vascular obstruction episodes (VOC) and pain episodes and avert organ injury. These medications typically do not possess a function during acute episodes. Hydroxy carbamide, or hydroxyurea, was the initial medication approved by the FDA for utilization in individuals with SCA. Nevertheless, the USFDA approved hydroxyurea for paediatric individuals two years and above only in 2017 based on the ESCORT HU trial. Disease-Modifying Medications/Therapy. The objective of disease-modifying therapy in individuals with SCA is to modify the kinetics of sickle erythrocytes. Hydroxyurea accomplishes this by elevating the concentration of fetal haemoglobin (HbF). Hydroxyurea: This is a ribonucleotide reductase inhibitor that elevates the concentration of HbF in individuals with SCD. It not only elevates the intracellular concentration of HbF but also elevates the number of erythrocytes containing HbF. Beyond this, hydroxyurea also diminishes the number of circulating reticulocytes and leukocytes, raises the volume of an RBC with high MCV noted in individuals receiving hydroxyurea, diminishes the deformability of RBC, enhances the flow of blood through capillaries, and modifies the expression of adhesion molecules hence preventing vascular obstruction episodes. [48]

Infants 9 months of age and older, children, and adolescents with SCA offer hydroxyurea regardless of clinical severity to diminish SCA-related complications including pain, dactylitis, ACS, anaemia.

For those with chronic kidney disease, taking erythropoietin and hydroxyurea can be added to improve anaemia.

DO NOT administer hydroxyurea to pregnant women and lactating mothers who choose to breastfeed their babies. Clinical utilization of hydroxyurea:

Dosing for adults: Start with 15 mg/kg/day. Round up to the closest 500 mg. For individuals with CKD- start at 5 to 10 mg/kg/day.

Dosing for infants and children: start at 20 mg/kg/day

Increments are to be accomplished every eight weeks in aliquots of 5mg/kg to a maximum of 35 mg/kg/day. [49]

Adverse events:

Myelotoxicity is the most frequent and most substantiated adverse effect of hydroxyurea. The remainder of the adverse effects reported in the literature, especially carcinogenesis and leukemia, have never been demonstrated in large studies.

Avoid the utilization of hydroxyurea in individuals with leg ulcers. Voxelotor: Voxelotor functions by inhibiting the polymerization of HbS and increasing the attraction for oxygen. It is dosed at 1500 mg by mouth daily and is approved for SCA treatment in individuals 12 years of age and older. Voxelotor can be administered with or without hydroxyurea. USFDA approved it in 2019 based on the results of the phase 3 HOPE trial which is Haemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization evaluating voxelotor with 1500 mg versus 900 mg versus placebo in 1:1:1 design. The most frequent adverse reactions are headache, diarrhoea, abdominal pain, nausea, fatigue, rash, and pyrexia. Voxelotor interferes with high-performance liquid chromatography (HPLC). Therefore, the haemoglobin quantification is not accurate when the individual is on voxelotor. HPLC should be performed when the individual is off therapy. Also, the utilization of voxelotor may increase the Hb, but there is no evidence to suggest discontinuation of exchange transfusion in individuals receiving this for cerebrovascular accident prophylaxis L-Glutamine: Glutamine is the most plentiful amino acid found in the human body. It is not an essential amino acid under normal circumstances, but in individuals with SCA, a high haemolysis rate elevates the demand for glutamine. L-glutamine is available in a medical formulation. The exact mechanism by which L-glutamine acts is still unclear. It is believed to work by scavenging for reactive oxygen species and functioning as a substrate for the regeneration of nitrous oxide, NAD, and NADH. The USFDA granted approval for L-glutamine in 2017 following favourable outcomes from the Pase III clinical Trial. [50]

The recent approvals of newer agents and the emergence of gene-editing techniques have expanded the options for SCA individuals. Also, extending the advantage of HSCT to low-income countries remains a significant challenge. Future Perspectives Gene editing is a new therapy focus whereby researchers attempt to elevate the HbF level in individuals with SCA. This technique is being developed alongside HSCT. Many approaches to gene editing are in clinical trials right now. Viral gene addition utilizing lentivirus: The technique aims to add a modified beta or gamma-globin gene to diminish the HbS component and elevate the HbA which is beta-globin gene or the HbF which is gamma-globin gene. [51]

Prognosis

The majority of the survival information in individuals with SCA does not account for the introduction of new medications. The Cooperative Study of Sickle Cell Disease (CSSCD) conducted between 1978-88 documented the median age of mortality for women and men as 42 and 48 years, respectively. This research also revealed that acute chest syndrome, kidney failure, seizures, elevated leukocyte count, and reduced concentrations of HbF were related to an increased likelihood of premature mortality in individuals with SCA. More contemporary research has revealed that elevated tricuspid regurgitant jet velocity on echocardiography, extended QTc interval, pulmonary hypertension, elevated N-terminal pro-brain natriuretic peptide, clinical history of asthma and respiratory wheezing, clinical history of end-stage kidney disease necessitating dialysis, and the intensity of haemolysis are independent risk elements towards premature mortality in individuals with SCA. [52] More contemporary information combining nine research studies from Europe and North America which evaluated 3257 individuals listed the following as predictors of mortality: Age with per 10-year elevation in age.

Tricuspid regurgitant jet velocity 2.5 m/s or greater

Reticulocyte count

Log of N-terminal-pro-brain natriuretic peptide

Fetal haemoglobin with the approval of newer medications including voxelotor and crizanlizumab in 2019, increased utilization of hematopoietic stem cell transplant, and exploration of newer techniques like gene therapy, survival is anticipated to elevate along with the quality of life. [53]

Complication

Complications SCA can result in acute complications and chronic complications acute complications: The majority of acute complications are related to blockage of the small to medium-sized blood vessels and occasionally large-sized blood vessels owing to polymerization of HbS and haemolysis. Acute chest syndrome

Sequestration episodes: splenic or hepatic sequestration

Fat embolism

Bone infarction or necrosis

Coagulopathy: elevates the likelihood of both arterial and venous blood clots- cerebrovascular accident, cardiac infarction, venous thrombosis

Ophthalmic: vitreous haemorrhage, retinal detachment, retinal artery or vein blockage

Aplastic episodes: in relation to parvovirus infection

Papillary necrosis Chronic Complications Postponed growth and development and growth restriction [54]

Cardiac: cardiac enlargement, heart muscle disease, left ventricular hypertrophy, irregular heartbeat; congestive cardiac failure

Pulmonary: pulmonary fluid accumulation, sickle cell lung condition, pulmonary hypertension

Hepatobiliary: liver enlargement, intrahepatic cholestasis, gallstone formation, viral hepatitis

Splenic complications: spleen enlargement, reduced spleen function, absence of spleen

Renal: acute and chronic kidney failure, kidney infection, renal medullary carcinoma

Musculoskeletal: degenerative modifications, bone infection, infectious arthritis, bone tissue death, reduced bone density or osteoporosis

Neurologic: aneurysm, cognitive impairment

Ophthalmic: proliferative sickle retinopathy, vitreous haemorrhage, retinal detachment, non-proliferative retinal modifications

Endocrine: primary hypogonadism, pituitary insufficiency, hypothalamic insufficiency

Iron accumulation owing to repeated transfusions and chronic haemolysis. [55]

Deterrence and Patient Education

SCA is a weakening condition that impacts an individual physically and possesses substantial emotional and psychological consequences. The social stigma of being identified with SCA has been extensively recorded. Numerous SCA individuals are incorrectly characterized as medication seekers and opioid misusers owing to the requirement for an exceptionally elevated quantity of opioids for pain management. Additionally, repeated encounters with various healthcare providers including in the emergency facilities, hospital stays, etc. Can result in unpredictable care. In such circumstances, the individuals need to be a champion for themselves. The following aspects can function as a framework for individual education. Demonstrate regularity in outpatient medical facilities and present yourself for your scheduled visits. Consistency in appointments to your healthcare providers facilitates to establish confidence within the healthcare framework. [56] Address pain necessities for pain medications with your healthcare provider with a receptive approach- They may seem limiting in prescribing pain medications, particularly opioids. Nevertheless, they are attempting to assist you by safeguarding you against excessive dosing. Utilize the identical emergency facility, or minimally the emergency facility within the identical hospital network. It is advantageous and facilitates in establishing familiarity with the personnel who function in that emergency facility. It also permits convenient accessibility to your personalized strategy of care, which your healthcare provider formulates for such circumstances. Compliance to disease-modifying therapy will assist diminish the occurrences of pain episodes and avert long-term organ injury. Always remain open to alternative approaches of obtaining management over pain including music therapy, self-hypnosis, and deep muscle relaxation. Individuals can implement protective strategies- maintain warmth and avoid contact with extreme temperatures, sufficient hydration, and respiratory exercises at home. [57]

Enhancing Healthcare Team Outcomes

Enhancing Healthcare Team Outcomes SCA is a widespread condition that impacts the complete organism. The condition not only presents with physical manifestations including pain episodes, organ injury, etc. But also possesses multiple psychological-social ramifications. The majority of individuals with SCA belong to the African-American population and a smaller proportion to Hispanic and other populations, which renders them susceptible to specific biases. [58] Furthermore, the elevated requirement for opioids to manage chronic pain renders the circumstances considerably more demanding. All healthcare providers must set aside their inherent bias when providing care for an individual with SCA, functioning cooperatively as an inter-professional collective. Nearly all medical specialties require involvement in managing individuals with SCA. Nevertheless, the haematology collective dedicated to providing care for SCA individuals must serve as the principal physicians for these individuals. Medical specialties including ophthalmology, orthopaedics, psychiatry, gastroenterology, and cardiovascular medicine engage intimately with SCA individuals. Nevertheless, this does not reduce the significance of other medical specialties. [59] Pharmacy and nursing also full-fill an essential function. With the introduction of newer medications and infusions and SCA impacting hepatic and renal function, pharmacists and nursing specialists are necessary to guarantee safe dosage and medication administration to the individual. The information presented here originates predominantly from extensive and limited randomized clinical investigations. Limited components of care presented here originate from cohort and case-control investigations. [60]

Conclusion

Sickle cell anemia remains one of the most challenging hereditary blood disorders worldwide, with significant morbidity and mortality particularly in low-resource settings. Although the molecular basis of the disease has been well-understood for decades, the clinical burden continues to be shaped by socioeconomic disparities, limited access to early diagnosis, inadequate follow-up, and delayed initiation of disease-modifying therapies. Advancements in newborn screening, improved understanding of haemolysis and vaso-occlusion, and deeper insights into the immunologic and oxidative contributors to disease have transformed the clinical approach to SCA.

The introduction of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab, along with the expanding role of hematopoietic stem cell transplantation and emerging gene-editing technologies, has significantly broadened the therapeutic landscape. These innovations not only reduce complications but also offer realistic prospects for long-term disease control and potential cure. Nevertheless, global disparities persist, and access to these therapies remains limited for many high-risk populations.

Comprehensive care—centered on early detection, timely prophylaxis, individualized pain management, patient education, and continuous primary care engagement—remains the cornerstone of improving outcomes in children and adults with SCA. As research advances and newer therapies evolve, strengthening healthcare systems, reducing social barriers, and ensuring equitable access are essential steps toward reducing disease burden and improving overall survival and quality of life for individuals living with sickle cell anemia.

References

[1] H. JB, “Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anaemia,” *Archives of Internal Medicine ,* vol. 6, no. 5, pp. 517-521, 1910.

[2] R. DC, “Sickle-cell disease,” *The Lancet,* vol. 376, no. 9757, pp. 2018-2031, 2010.

[3] R. DC, “Sickle-cell disease,” *The Lancet,* vol. 376, no. 9757, pp. 2018-2031, 2010.

[4] P. FB, “Sickle Cell Disease,” *New England Journal of Medicine,* vol. 376, no. 16, pp. 1561-1573, 2017.

[5] M. B, “Global epidemiology of haemoglobin disorders and derived service indicators,” *Bulletin of the World Health Organization,* vol. 86, no. 6, pp. 480-487, 2008.

[6] K. PY, “ACG: Clinical Guideline: Evaluation of Abnormal Liver Chemistries,” *American Journal of Gastroenterology ,* vol. 112, no. 1, pp. 18-35, 2017.

[7] M. CP, “How we treat sickle cell patients with leg ulcers,” *American Journal of Hematology,* vol. 91, no. 1, pp. 22-30, 2016.

[8] H. RC, "Evolution of Hemoglobin and its Genes," *Cold Spring Harbor Perspectives in Medicine,* vol. 2, no. 12, p. a011627, 2012.

[9] H. AV, Postgraduate Haematology, Wiley-Blackwell, 2016.

[10] H. AV, Postgraduate Haematology, 7. edition, Ed., Wiley-Blackell, 2016.

[11] S. MH, Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2. edition, Ed., Cambridge University Press, 2009.

[12] R. DC, "Sickle-cell disease," *Lancet ,* vol. 376, no. 9757, pp. 2018-2031, 2010.

[13] R. DC, "Sickle-cell disease," *Lancet,* vol. 376, no. 9757, pp. 2081-2031, 2010.

[14] S. MH, "Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management," *Cambridge University Press ,* 2009.

[15] R. DC, "Sickle-cell disease," *Lancet,* vol. 376, no. 9757, pp. 2018-2031, 2010.

[16] K. GJ, "Sickle cell disease," *Nature Reviews Disease Primers,* vol. 4, 2018.

[17] M. A, "Sickle Cell Anemia," *StatPearls,* 2023.

[18] C. f. D. C. a. P. (CDC), "Data and Statistics on Sickle Cell Disease," Updated May 15, 2024. [Online].

[19] M. A, "Sickle Cell Anemia," *StatPearls Publishing/ NCBI Bookshelf,* 2023.

[20] P. FB, "Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions," *Plos Medicine,* vol. 10, no. 7, p. e1001484, 2013.

[21] E. Yanni, "Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002," *The Journal of Pediatrics,* vol. 154, no. 4, pp. 541-545, 2009.

[22] G. 2. S. C. D. Collaborators, "Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021," *The Lancet Haematology,* vol. 10, no. 8, pp. e585-e599, 2023.

[23] R. DC, "Sickle-cell disease," *Nature Reviews Disease Primers,* vol. 3, p. 17056, 2017.

[24] S. MH, "Overview of pathophysiology and rationale for treatment of sickle cell anemia," *Annual Review of Medicine ,* vol. 48, pp. 313-326, 1997.

[25] S. K, "Structural and functional insight of sphingosine-1-phosphate-mediated pathogenic metabolic reprogramming in sickle cell disease," *Scientific Reports,* vol. 7, p. 15281, 2017.

[26] W. Q, "The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications," *Antioxidants,* vol. 10, no. 10, p. 1608, 2021.

[27] G. J, "Intravascular hemolysis and the pathophysiology of sickle cell disease," *Journal of Clinical Investigation,* vol. 127, no. 3, pp. 750-760, 2017.

[28] A.-K. A, Sickle Cell Anemia, Treasure Island (FL), USA: StatPearls Publishing, 2023.

[29] M. RA, Peripheral Blood Smear, Elsevier, 2022.

[30] Y. Daniel, "Non-Invasive Prenatal Diagnosis (NIPD) of Sickle-Cell Disease By Massively Parallel Sequencing of Cell-Free Fetal DNA in Maternal Serum," *Blood(American Society of Hematology),* vol. 134, 2019.

[31] N. D, "Phenotypic Modulation in Sickle Cell Anemia: Two Sub-Phenotypes Based on Hemolysis Rate and Viscosity," *Haematologica,* vol. 96, no. 11, pp. 1589-1595, 2011.

[32] B. AM, "Key Components of Pain Management for Children and Adults with Sickle Cell Disease," *Hematology/Oncology Clinics of North America ,* vol. 32, no. 3, pp. 535-550, 2018.

[33] C. ST, "Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications," *Hematology/Oncolgy Clinics of North America,* vol. 30, no. 3, pp. 591-608, 2016.

[34] Y. BP, "Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by the Expert Panel," *JAMA(Journal of the American Medical Association),* vol. 312, no. 10, pp. 1033-1048, 2014.

[35] E.-H. N, "Newborn Screening for Sickle Cell Disease (SCD) in the USA and Canada," *International Journal of Neonatal Screening,* vol. 4, no. 4, p. Article 36, 2018.

[36] S. AV, "Comparative study of solubility and hemoglobin electrophoresis with high performance liquid chromatography (HPLC) for screening of hemoglobinopathies and thalassemia," *International Archives of Integrated Medicine ,* vol. 6, no. 3, pp. 111-126, 2019.

[37] V. EP, "Acute chest syndrome in sickle cell disease," *New England Journal of Medicine (NEJM),* vol. 342, no. 25, pp. 1904-1909, 2000.

[38] V. EP, "Acute Chest Syndrome in sickle cell disease," *New England Journal of Medicine,* vol. 342, no. 25, pp. 1904-1909, 2000.

[39] H. J, "Guideline on the management of acute chest syndrome in sickle cell disease," *British Journal of Haematology,* vol. 169, no. 4, pp. 492-505, 2015.

[40] A. RJ, "Sickle cell and the brain: cerebrovascular accidents and silent cerebral infarcts," *Blood,* vol. 97, no. 1, pp. 15-19, 2001.

[41] Y. BP, "Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members," *Journal of the American Medical Association (JAMA),* vol. 312, no. 10, pp. 1033-1048, 2014.

[42] L. a. B. I. (. National Heart, "Evidence-Based Management of Sickle-Cell Disease: Expert Panel Report 2014," U.S.Department of Health and Human Services, Bethesda,Maryland, 2014.

[43] L. a. B. I. (. National Heart, "Evidence-Based Management of Sickle Cell Disease: Expert Panel Report 2014," U.S.Department of Health and Human Services, Bethesda, Maryland, 2014.

[44] L. a. B. I. (. National Heart, "Evidence-Based Management of Sickle Cell Disease: Expert Panel Report 2014," U.S.Department of Health and Human Services, Bethesda, Maryland, 2014.

[45] L. a. B. I. (. National Heart, "Evidence-Based Management of Sickle Cell Disease: Expert Panel Report 2014," U.S.Department of Health and Human Services , Bethesda, Maryland, 2014.

[46] S. (. e. team), Sickle Cell Anemia, Treasure Island, FL: StatPearls Publishing, 2025.

[47] M. M. P. Edition, "Overview of Hemolytic Anemia," in *Hematology & Oncology, Anemias caused by hemolysis* , MSD Manuals, 2025.

[48] L. R. M, "The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia," *Journal of Clinical Medicine,* vol. 13, no. 21, p. 6404, 2024.

[49] L. a. B. I. (. National Heart, "Evidence-Based Management of Sickle Cell Diseaase: Expert Panel Report,2014," 2014.

[50] N. Y, "A Phase 3 Trial of L-Glutamine in Sickle Cell Disease," *New England Journal of Medicine,* vol. 379, no. 3, pp. 226-235, 2018.

[51] K. J, "Gene therapy for sickle cell disease: Current approaches and promising future directions," *Blood,* vol. 140, no. 11, pp. 1205-1217, 2022.

[52] P. OS, "Mortality in sickle cell disease-life expectancy and risk factors for early death," *New England Journal of Medicine,* vol. 330, no. 23, pp. 1639-1644, 1994.

[53] D. MR, "Predictors of mortality in adults with sickle cell disease: A meta-analysis of cohort studies from Europe and North America," *Blood Advances,* vol. 7, no. 4, pp. 789-801, 2023.

[54] M. RM, "Complications of Sickle Cell Disease and Current Management Approaches," *NCBI Bookshef,* 2020.

[55] K. GJ, "Sickle Cell Disease," *Nature Reviews Disease Primers,* vol. 4, no. 1, p. 18010, 2018.

[56] S. S, "Opioid management in sickle cell disease: Tolerance, dependence and hyperalgesia," *Journal of Pain Research,* vol. 13, pp. 1125-1136, 2020.

[57] M. N. &. J. C, "Understanding the Self-Management Practices of Young Adults with Sickle cell disease," *J Sickle Cell Dis Hemoglobinopathies,* pp. 76-87, 2017.

[58] O. TC, "Psychosocial challenges of persons with sickle cell anemia: A narrative review," *Nigerian Journal of Clinical Practice ,* vol. 26, no. 12, pp. 1-8, 2023.

[59] S. WR, "Optimizing the management of chronic pain in sickle cell disease," *Journal of Pain Research,* vol. 13, pp. 3225-3236, 2020.

[60] O. O, "Roles of pharmacist in the management of sickle cell disease in adults: A narrative review," *Journal of the American College of Clinical Pharmacy,* vol. 7, no. 3, pp. 327-338, 2024.